Published in Proc Natl Acad Sci U S A on May 12, 2008
The Role of SNP rs2910164 in Patients Treated With Immune Checkpoint Inhibitors | NCT04038996
Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer (2010) 7.39
MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol (2011) 5.46
Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer (2011) 5.12
Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell (2010) 4.57
Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. Nat Genet (2009) 3.46
Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res (2009) 3.40
Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis (2009) 3.40
A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans. J Clin Invest (2009) 3.03
Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res (2010) 2.82
A robust approach to identifying tissue-specific gene expression regulatory variants using personalized human induced pluripotent stem cells. PLoS Genet (2009) 2.78
Regulation of MicroRNA Biogenesis: A miRiad of mechanisms. Cell Commun Signal (2009) 2.27
Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. Proc Natl Acad Sci U S A (2009) 2.20
MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases. Transl Res (2011) 2.15
SNPs in human miRNA genes affect biogenesis and function. RNA (2009) 2.08
Beyond secondary structure: primary-sequence determinants license pri-miRNA hairpins for processing. Cell (2013) 2.03
Environmental chemical exposures and human epigenetics. Int J Epidemiol (2011) 1.97
Altered microRNA expression profile with miR-146a upregulation in CD4+ T cells from patients with rheumatoid arthritis. Arthritis Res Ther (2010) 1.94
MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics (2009) 1.88
miR-155 promotes T follicular helper cell accumulation during chronic, low-grade inflammation. Immunity (2014) 1.82
Discovery of common variants associated with low TSH levels and thyroid cancer risk. Nat Genet (2012) 1.81
A functional variant in microRNA-146a promoter modulates its expression and confers disease risk for systemic lupus erythematosus. PLoS Genet (2011) 1.68
Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer Res (2009) 1.68
MicroRNAs as biomarkers in rheumatic diseases. Nat Rev Rheumatol (2010) 1.59
Association of microRNA-196a-2 gene polymorphism with gastric cancer risk in a Chinese population. Dig Dis Sci (2009) 1.58
The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors. PLoS Genet (2009) 1.57
The emerging role of MIR-146A in the control of hematopoiesis, immune function and cancer. J Hematol Oncol (2012) 1.56
A brief review on the mechanisms of miRNA regulation. Genomics Proteomics Bioinformatics (2009) 1.56
MicroRNAs, macrocontrol: regulation of miRNA processing. RNA (2010) 1.56
MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration. Int J Cancer (2011) 1.55
Genetic variants in selected pre-microRNA genes and the risk of squamous cell carcinoma of the head and neck. Cancer (2010) 1.45
Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells. Oncogene (2012) 1.44
MicroRNAs: critical mediators of differentiation, development and disease. Swiss Med Wkly (2009) 1.43
Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer (2011) 1.38
Effects of common polymorphisms rs11614913 in miR-196a2 and rs2910164 in miR-146a on cancer susceptibility: a meta-analysis. PLoS One (2011) 1.37
Comprehensive review of genetic association studies and meta-analyses on miRNA polymorphisms and cancer risk. PLoS One (2012) 1.36
Genome-wide transcriptional profiling reveals microRNA-correlated genes and biological processes in human lymphoblastoid cell lines. PLoS One (2009) 1.35
Integrative functional genomics identifies an enhancer looping to the SOX9 gene disrupted by the 17q24.3 prostate cancer risk locus. Genome Res (2012) 1.35
MicroRNAs in thyroid cancer. J Clin Endocrinol Metab (2011) 1.35
Functional integration of microRNAs into oncogenic and tumor suppressor pathways. Cell Cycle (2008) 1.33
Reduced miR-146a increases prostaglandin E₂in chronic obstructive pulmonary disease fibroblasts. Am J Respir Crit Care Med (2010) 1.33
MicroRNAs: molecular features and role in cancer. Front Biosci (Landmark Ed) (2012) 1.32
microRNA and cancer. AAPS J (2010) 1.32
MiR-146a in Immunity and Disease. Mol Biol Int (2011) 1.28
A dual role for KRT81: a miR-SNP associated with recurrence in non-small-cell lung cancer and a novel marker of squamous cell lung carcinoma. PLoS One (2011) 1.28
MicroRNAs: tools for cancer diagnostics. Gut (2009) 1.25
Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer. Carcinogenesis (2009) 1.23
Differential miRNA expression profiles in variants of papillary thyroid carcinoma and encapsulated follicular thyroid tumours. Br J Cancer (2009) 1.21
Functional genetic variation of human miRNAs and phenotypic consequences. Mamm Genome (2008) 1.20
Cumulative risk impact of five genetic variants associated with papillary thyroid carcinoma. Thyroid (2013) 1.20
MicroRNAs in inflammatory bowel disease. Inflamm Bowel Dis (2011) 1.19
Signatures of purifying and local positive selection in human miRNAs. Am J Hum Genet (2009) 1.18
SNPing cancer in the bud: microRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancer. Pharmacol Ther (2012) 1.18
A functional varient in microRNA-146a is associated with risk of esophageal squamous cell carcinoma in Chinese Han. Fam Cancer (2010) 1.17
Genetic association of miRNA-146a with systemic lupus erythematosus in Europeans through decreased expression of the gene. Genes Immun (2012) 1.16
Evaluation of SNPs in miR-196-a2, miR-27a and miR-146a as risk factors of colorectal cancer. World J Gastroenterol (2012) 1.14
In-depth characterization of the microRNA transcriptome in normal thyroid and papillary thyroid carcinoma. J Clin Endocrinol Metab (2013) 1.14
Genetic polymorphisms in pre-microRNA genes as prognostic markers of colorectal cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.14
Lack of association of two common polymorphisms rs2910164 and rs11614913 with susceptibility to hepatocellular carcinoma: a meta-analysis. PLoS One (2012) 1.12
Genetic Predisposition to Familial Nonmedullary Thyroid Cancer: An Update of Molecular Findings and State-of-the-Art Studies. J Oncol (2010) 1.12
Correlation between pre-miR-146a C/G polymorphism and gastric cancer risk in Chinese population. World J Gastroenterol (2010) 1.11
Thyroid hormone receptor beta (THRB) is a major target gene for microRNAs deregulated in papillary thyroid carcinoma (PTC). J Clin Endocrinol Metab (2010) 1.10
A functional polymorphism in the pre-miR-146a gene is associated with risk and prognosis in adult glioma. J Neurooncol (2011) 1.09
MicroRNAs in mutagenesis, genomic instability, and DNA repair. Semin Oncol (2011) 1.09
Association between two genetic variants in miRNA and primary liver cancer risk in the Chinese population. DNA Cell Biol (2011) 1.09
SomamiR: a database for somatic mutations impacting microRNA function in cancer. Nucleic Acids Res (2012) 1.08
Comprehensive analysis of the impact of SNPs and CNVs on human microRNAs and their regulatory genes. RNA Biol (2009) 1.07
Association study of common genetic variants in pre-microRNAs in patients with ulcerative colitis. J Clin Immunol (2010) 1.06
Association between microRNA polymorphisms and cancer risk based on the findings of 66 case-control studies. PLoS One (2013) 1.05
MicroRNA dysregulation as a prognostic biomarker in colorectal cancer. Cancer Manag Res (2014) 1.05
microRNAs: a newly described class of encoded molecules that play a role in health and disease. Hippokratia (2010) 1.05
Pharmacological studies of the mechanism and function of interleukin-1beta-induced miRNA-146a expression in primary human airway smooth muscle. Respir Res (2010) 1.05
The association between four genetic variants in microRNAs (rs11614913, rs2910164, rs3746444, rs2292832) and cancer risk: evidence from published studies. PLoS One (2012) 1.03
Cancer microRNAs: from subtype profiling to predictors of response to therapy. Trends Mol Med (2011) 1.03
A novel mutation within the MIR96 gene causes non-syndromic inherited hearing loss in an Italian family by altering pre-miRNA processing. Hum Mol Genet (2011) 1.03
miR-146a promotes the initiation and progression of melanoma by activating Notch signaling. Elife (2014) 1.02
Increased risk of breast cancer associated with CC genotype of Has-miR-146a Rs2910164 polymorphism in Europeans. PLoS One (2012) 1.01
The Influence of 3'UTRs on MicroRNA Function Inferred from Human SNP Data. Comp Funct Genomics (2011) 1.00
Novel genetic variants in miR-191 gene and familial ovarian cancer. BMC Cancer (2010) 0.98
rs4919510 in hsa-mir-608 is associated with outcome but not risk of colorectal cancer. PLoS One (2012) 0.98
Targeting human microRNA genes using engineered Tal-effector nucleases (TALENs). PLoS One (2013) 0.98
A precursor microRNA in a cancer cell nucleus: get me out of here! Cell Cycle (2011) 0.97
MicroRNAs and the regulation of intestinal homeostasis. Front Genet (2014) 0.97
Functional polymorphisms in two pre-microRNAs and cancer risk: a meta-analysis. Int J Mol Epidemiol Genet (2010) 0.97
MicroRNA sequence polymorphisms and the risk of different types of cancer. Sci Rep (2014) 0.97
miRNAs in the pathogenesis of oncogenic human viruses. Cancer Lett (2010) 0.96
Pre-microRNA variants predict HPV16-positive tumors and survival in patients with squamous cell carcinoma of the oropharynx. Cancer Lett (2012) 0.96
A genetic variant in pre-miR-27a is associated with a reduced renal cell cancer risk in a Chinese population. PLoS One (2012) 0.96
Combined effect of miR-146a rs2910164 G/C polymorphism and Toll-like receptor 4 +3725 G/C polymorphism on the risk of severe gastric atrophy in Japanese. Dig Dis Sci (2010) 0.96
Bladder cancer epidemiology and genetic susceptibility. J Biomed Res (2013) 0.95
Regulation of microRNA biogenesis and turnover by animals and their viruses. Cell Mol Life Sci (2013) 0.95
MiR-886-3p regulates cell proliferation and migration, and is dysregulated in familial non-medullary thyroid cancer. PLoS One (2011) 0.94
Differential expression profile and genetic variants of microRNAs sequences in breast cancer patients. PLoS One (2012) 0.94
The regulatory roles of microRNA-146b-5p and its target platelet-derived growth factor receptor α (PDGFRA) in erythropoiesis and megakaryocytopoiesis. J Biol Chem (2014) 0.94
A microRNA expression signature for the prognosis of oropharyngeal squamous cell carcinoma. Cancer (2012) 0.94
A pre-microRNA-149 (miR-149) genetic variation affects miR-149 maturation and its ability to regulate the Puma protein in apoptosis. J Biol Chem (2013) 0.93
MicroRNA polymorphisms: a giant leap towards personalized medicine. Per Med (2009) 0.93
MicroRNA-related sequence variations in human cancers. Hum Genet (2013) 0.93
Genomic sequence matters: a SNP in microRNA-146a can turn anti-apoptotic. Cell Cycle (2009) 0.92
A germline mutation in SRRM2, a splicing factor gene, is implicated in papillary thyroid carcinoma predisposition. Sci Rep (2015) 0.91
Lack of association between miR-27a, miR-146a, miR-196a-2, miR-492 and miR-608 gene polymorphisms and colorectal cancer. Sci Rep (2014) 0.91
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer (2006) 46.47
MicroRNA signatures in human cancers. Nat Rev Cancer (2006) 46.29
NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A (2006) 21.58
MicroRNA maturation: stepwise processing and subcellular localization. EMBO J (2002) 19.47
Fast and effective prediction of microRNA/target duplexes. RNA (2004) 18.10
NF-kappaB at the crossroads of life and death. Nat Immunol (2002) 12.98
miRNAs, cancer, and stem cell division. Cell (2005) 12.15
microRNAs as oncogenes and tumor suppressors. Dev Biol (2006) 10.68
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res (2003) 8.67
The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A (2005) 8.60
Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst (1994) 6.27
BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst (2003) 6.20
MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer (2006) 4.11
Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA. Hum Mol Genet (2007) 4.08
PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell (1990) 3.98
Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish Family-Cancer Database. Int J Cancer (2002) 3.55
MicroRNAs and immunity: tiny players in a big field. Immunity (2007) 3.01
BRAF mutations in papillary carcinomas of the thyroid. Oncogene (2003) 2.94
Epstein-Barr virus latent membrane protein 1 induces cellular MicroRNA miR-146a, a modulator of lymphocyte signaling pathways. J Virol (2007) 2.88
A novel assay for viral microRNA function identifies a single nucleotide polymorphism that affects Drosha processing. J Virol (2006) 2.71
A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2. Am J Hum Genet (1998) 1.81
Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet (2001) 1.68
Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression. Oncogene (1997) 1.57
Oncogenic and anti-apoptotic activity of NF-kappa B in human thyroid carcinomas. J Biol Chem (2004) 1.32
BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation. Endocrinology (2006) 1.25
Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. Cancer Res (1994) 1.22
High basal levels of functional toll-like receptor 3 (TLR3) and noncanonical Wnt5a are expressed in papillary thyroid cancer and are coordinately decreased by phenylmethimazole together with cell proliferation and migration. Endocrinology (2007) 1.04
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Hereditary colorectal cancer. N Engl J Med (2003) 11.86
Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med (2005) 9.39
The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A (2005) 8.60
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol (2011) 7.65
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA (2013) 5.71
Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol (2008) 5.47
Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res (2006) 4.26
Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell (2007) 3.58
Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. Nat Genet (2009) 3.46
Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol (2013) 3.37
The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology (2008) 3.35
Germline allele-specific expression of TGFBR1 confers an increased risk of colorectal cancer. Science (2008) 3.16
Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med (2012) 2.82
Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology (2005) 2.80
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol (2009) 2.77
Identification of Lynch syndrome among patients with colorectal cancer. JAMA (2012) 2.77
Reprogramming of miRNA networks in cancer and leukemia. Genome Res (2010) 2.65
KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol (2004) 2.61
Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst (2009) 2.56
A role for the eIF4E-binding protein 4E-T in P-body formation and mRNA decay. J Cell Biol (2005) 2.51
Mutations in U4atac snRNA, a component of the minor spliceosome, in the developmental disorder MOPD I. Science (2011) 2.47
Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol (2005) 2.41
Long-range PCR facilitates the identification of PMS2-specific mutations. Hum Mutat (2006) 2.39
Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer. Surgery (2012) 2.29
BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood (2003) 2.23
Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. Proc Natl Acad Sci U S A (2009) 2.20
PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol (2002) 2.16
B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci U S A (2010) 2.03
Role of cancer-associated stromal fibroblasts in metastatic colon cancer to the liver and their expression profiles. Oncogene (2004) 1.97
The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type. Proc Natl Acad Sci U S A (2012) 1.92
The functional cobalamin (vitamin B12)-intrinsic factor receptor is a novel complex of cubilin and amnionless. Blood (2003) 1.91
Cancer risks for relatives of patients with serrated polyposis. Am J Gastroenterol (2012) 1.88
Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci U S A (2007) 1.84
RNA helicase A is necessary for translation of selected messenger RNAs. Nat Struct Mol Biol (2006) 1.83
Cohen syndrome is caused by mutations in a novel gene, COH1, encoding a transmembrane protein with a presumed role in vesicle-mediated sorting and intracellular protein transport. Am J Hum Genet (2003) 1.83
Discovery of common variants associated with low TSH levels and thyroid cancer risk. Nat Genet (2012) 1.81
Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene. Am J Hum Genet (2003) 1.80
A susceptibility locus for papillary thyroid carcinoma on chromosome 8q24. Cancer Res (2009) 1.77
miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. Blood (2012) 1.77
Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes. Proc Natl Acad Sci U S A (2004) 1.75
Amnionless, essential for mouse gastrulation, is mutated in recessive hereditary megaloblastic anemia. Nat Genet (2003) 1.71
Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1. Gastroenterology (2005) 1.70
Identification of a cytoplasmic complex that adds a cap onto 5'-monophosphate RNA. Mol Cell Biol (2009) 1.67
The search for unaffected individuals with Lynch syndrome: do the ends justify the means? Cancer Prev Res (Phila) (2011) 1.66
Mycobacterium tuberculosis lipomannan blocks TNF biosynthesis by regulating macrophage MAPK-activated protein kinase 2 (MK2) and microRNA miR-125b. Proc Natl Acad Sci U S A (2011) 1.62
Somatic acquisition and signaling of TGFBR1*6A in cancer. JAMA (2005) 1.59
Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications. Eur J Hum Genet (2006) 1.59
Mismatch repair gene PMS2: disease-causing germline mutations are frequent in patients whose tumors stain negative for PMS2 protein, but paralogous genes obscure mutation detection and interpretation. Cancer Res (2004) 1.55
Exome sequencing reveals germline NPAT mutation as a candidate risk factor for Hodgkin lymphoma. Blood (2011) 1.52
The frequency of Muir-Torre syndrome among Lynch syndrome families. J Natl Cancer Inst (2008) 1.49
Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol (2005) 1.46
Interleukin-1-inducible MCPIP protein has structural and functional properties of RNase and participates in degradation of IL-1beta mRNA. FEBS J (2009) 1.44
Evidence for heritable predisposition to epigenetic silencing of MLH1. Int J Cancer (2007) 1.43
Hereditary juvenile cobalamin deficiency caused by mutations in the intrinsic factor gene. Proc Natl Acad Sci U S A (2005) 1.41
Welcome to thyroid research. Thyroid Res (2008) 1.40
A+U-rich instability elements differentially activate 5'-3' and 3'-5' mRNA decay. Mol Cell Biol (2007) 1.38
Comment on: Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) among Endometrial Cancer Patients. Cancer Res (2007) 1.38
Infrequent detection of germline allele-specific expression of TGFBR1 in lymphoblasts and tissues of colon cancer patients. Cancer Res (2009) 1.38
Genetically heterogeneous selective intestinal malabsorption of vitamin B12: founder effects, consanguinity, and high clinical awareness explain aggregations in Scandinavia and the Middle East. Hum Mutat (2004) 1.38
Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol (2005) 1.37
Risk factors for colorectal cancer in patients with multiple serrated polyps: a cross-sectional case series from genetics clinics. PLoS One (2010) 1.36
Lymphomas diagnosed by percutaneous kidney biopsy. Am J Kidney Dis (2003) 1.34
Beta -Globin mRNA decay in erythroid cells: UG site-preferred endonucleolytic cleavage that is augmented by a premature termination codon. Proc Natl Acad Sci U S A (2002) 1.33
Identification and characterization of genomic rearrangements of MSH2 and MLH1 in Lynch syndrome (HNPCC) by novel techniques. Hum Mutat (2003) 1.32
Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53. Proc Natl Acad Sci U S A (2002) 1.32
Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol (2004) 1.31
Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin Cancer Res (2003) 1.31
Endonuclease-mediated mRNA decay involves the selective targeting of PMR1 to polyribosome-bound substrate mRNA. Mol Cell (2004) 1.28
Phenotypic diversity in patients with multiple serrated polyps: a genetics clinic study. Int J Colorectal Dis (2010) 1.27
Tgfbr1 haploinsufficiency is a potent modifier of colorectal cancer development. Cancer Res (2009) 1.26
A founder mutation of the MSH2 gene and hereditary nonpolyposis colorectal cancer in the United States. JAMA (2004) 1.26
Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma. Int J Cancer (2003) 1.25
Amnionless function is required for cubilin brush-border expression and intrinsic factor-cobalamin (vitamin B12) absorption in vivo. Blood (2005) 1.25
Cumulative risk impact of five genetic variants associated with papillary thyroid carcinoma. Thyroid (2013) 1.20
Allele-specific expression of TGFBR1 in colon cancer patients. Carcinogenesis (2010) 1.17
TGFBR1*6A may contribute to hereditary colorectal cancer. J Clin Oncol (2005) 1.16
Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol (2004) 1.16
rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer (2005) 1.15
In-depth characterization of the microRNA transcriptome in normal thyroid and papillary thyroid carcinoma. J Clin Endocrinol Metab (2013) 1.14
HABP2 Mutation and Nonmedullary Thyroid Cancer. N Engl J Med (2015) 1.13
BAALC, a novel marker of human hematopoietic progenitor cells. Exp Hematol (2003) 1.13
Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions. Mol Cell Endocrinol (2010) 1.13
SRGAP1 is a candidate gene for papillary thyroid carcinoma susceptibility. J Clin Endocrinol Metab (2013) 1.12
Identification of cytoplasmic capping targets reveals a role for cap homeostasis in translation and mRNA stability. Cell Rep (2012) 1.10
Thyroid hormone receptor beta (THRB) is a major target gene for microRNAs deregulated in papillary thyroid carcinoma (PTC). J Clin Endocrinol Metab (2010) 1.10
Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant. Eur J Haematol (2003) 1.09
Endonuclease-mediated mRNA decay requires tyrosine phosphorylation of polysomal ribonuclease 1 (PMR1) for the targeting and degradation of polyribosome-bound substrate mRNA. J Biol Chem (2004) 1.09
Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur J Haematol (2002) 1.08
Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid (2013) 1.07
Origins and prevalence of the American Founder Mutation of MSH2. Cancer Res (2008) 1.06
MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma. Am J Surg Pathol (2005) 1.06
Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease. PLoS One (2013) 1.06
Histologic features distinguish microsatellite-high from microsatellite-low and microsatellite-stable colorectal carcinomas, but do not differentiate germline mutations from methylation of the MLH1 promoter. Hum Pathol (2006) 1.06